Why $20 Kombucha and $3 Kombucha Are The Same Thing

Your $6 kombucha costs about $1.20 to make.

The $3 one next to it? About $0.90.

Same tea.

Same sugar.

Same fermentation.

Same slimy rubbery disc of bacteria and yeast sitting in a jar doing all the work.

One has a craft label and a story about a small-batch brewery in Auckland. The other has a mega-factory in Melbourne the size of two MCGs.

The difference on the shelf is $3. The difference in the bottle is almost nothing.

This is a multi-billion dollar global industry built on four ingredients your nan kept in her pantry.

And the economics are wilder than you think.

Before SCOBY Was Cool

Kombucha didn't invent fermented drinks. It barely even popularised them.

Kefir (fermented milk) has been around since the North Caucasus shepherds. Kvass, a fermented bread drink, kept Russian peasants going for centuries. Tepache (fermented pineapple) is still sold on street corners across Mexico for basically nothing. Jun tea uses honey instead of sugar and green tea instead of black.

All probiotic.

All cheap to produce.

None of them retail for $6 a bottle.

Kombucha's own origin is murky. Some sources trace it to the Qin Dynasty in China around 220 BCE. Others point to Eastern European folk traditions. What's not debatable: for most of its history, kombucha was a home-fermented drink. A jar on the counter.

A SCOBY passed between neighbours.

It cost nothing.

The transformation from folk remedy to commercial category happened almost entirely in one city: Los Angeles. In the mid-1990s. Because of one teenager who couldn't sleep.

A Teenager, A Buddhist Nun's SCOBY, and a Billion Dollars Walk Into A Bar

In 1995, a 17-year-old named GT Dave started brewing kombucha in his parents' kitchen in Bel Air.

His family had received a SCOBY from a friend, who'd gotten it from a Buddhist nun. When GT's mother Laraine was diagnosed with breast cancer in 1994, she drank the home-brewed kombucha through her chemotherapy. She beat the cancer. She credited the kombucha.

GT got obsessed.

He sold his first two cases to Erewhon Natural Foods in LA.

24 bottles.

Nearly all gone on day one.

He ran the entire operation from his bedroom, calling distributors and store owners using different voices to pretend he had employees.

A teenager in Bel Air.

Doing character voices on the phone.

Selling fermented tea from his parents' kitchen.

GT's Living Foods is now worth over $900 million. GT Dave owns 100% of it. Never taken outside funding. Never bought an ad. The company does an estimated $275 million in annual revenue and controls roughly 40% of the entire US kombucha market. His fermentary in Vernon, California, produces over a million bottles a year. He still ferments every batch for 30 days. Uses kiwi juice instead of cane sugar. Taste-tests every batch personally.

He drinks 8 to 12 bottles of his own kombucha every day. Over a gallon.

He's a billionaire.

His product is fermented tea.

Four ingredients and time.

The category he created from his bedroom is now worth somewhere between $3 billion and $5 billion globally, growing at 15% to 20% annually. And here's the detail that matters for everything that follows: GT Dave has turned down every single acquisition offer. In 2019, he donated $1 million of his own money to Kombucha Brewers International to establish a standard of identity for the product.

He was trying to protect the authenticity of a category he could see being hollowed out from the inside.

Everyone Else Cashed Out

GT held on. The rest of the industry took the cheque.

PepsiCo acquired KeVita in 2016 for an estimated $200 million. KeVita was doing about $40 million in tracked retail sales at the time. PepsiCo wanted into the functional beverage aisle, and KeVita gave them kombucha, sparkling probiotics, and apple cider vinegar tonics in one deal.

In mid-2025, Generous Brands acquired Health Ade for approximately $500 million. Health-Ade had grown from a Los Angeles farmers market stall in 2012 to nearly $250 million in annual retail sales across 65,000 US stores.

Same pattern every time. Founder starts brewing in a kitchen. Product connects with the wellness crowd. Distribution scales through Whole Foods, then conventional grocery. Private equity or big CPG writes a cheque.

GT watched two of his main competitors disappear into corporate platforms and stayed independent. His mother's cancer story. His bedroom brewery. His billion-dollar company that still ferments for 30 days.

The brand story is real because the operating reality backs it up.

That's increasingly rare in this category.

Building a Bottle From Scratch

Here's what it actually costs to produce a 330ml bottle of kombucha at commercial scale.

Tea: $0.03 to $0.06. Even organic, single-origin tea is cheap in bulk. A standard blend runs $4 to $8 per kilo, and you use roughly 10 grams per litre.

Sugar: $0.02 to $0.04. The SCOBY consumes most of it during fermentation. About 70 to 100 grams per litre at $0.70 to $1.00/kg for commercial organic cane sugar.

SCOBY: Free. It reproduces. Once you have a mother culture, you never buy another one.

Water: Negligible.

Flavouring: $0.05 to $0.15. Fruit juice concentrate, ginger, hibiscus.

Total raw ingredient cost per bottle: roughly $0.10 to $0.25.

Now add production reality. Glass bottle and cap: $0.12 to $0.20. Label: $0.03 to $0.08. Filling, capping, labelling labour: $0.05 to $0.10 at scale.

A well-run commercial operation lands a finished 330ml bottle somewhere between $0.44 and $1.25, depending on scale and automation. Industry benchmarks are consistent: COGS runs 25% to 35% of revenue. Gross margins sit between 50% and 70%.

Remedy sells at $2.99. Batchwell at $5.39. The production cost gap between them is maybe $0.30 to $0.50.

The retail price gap is $2.40.

That $2.40 is brand, scale, and supply chain.

It's not the tea.

When Australia Shows Up, You Lose

Remedy holds 40% of the New Zealand kombucha market. Lo Bros takes another significant chunk.

Sadly, Both Australian.

Both massive.

Remedy's fermentary in Dandenong South, Melbourne, houses over 1,000 pots of brewing kombucha. Founded by Sarah and Emmet Condon in 2012 on their kitchen bench. Now exporting to the UK, US, Canada, Singapore, and New Zealand, where they own the cheap end of every supermarket fridge.

Scale does three things small NZ brewers simply cannot match.

It crushes unit cost. Hundreds of thousands of bottles means cheaper glass, cheaper labels, cheaper labour per unit. Remedy produces a bottle for well under a dollar and still makes healthy margin at $2.99.

It funds shelf access. Slotting fees, promotional support, category reviews. The supermarket duopoly (Woolworths and Foodstuffs) doesn't hand shelf space to brands that can't move volume. Remedy and Lo Bros can afford to play. Small Kiwi brewers often can't.

And it enables production shortcuts. Lo Bros ships kombucha concentrate from Australia and adds carbonated water, sweeteners, and probiotics at destination. Cheaper than shipping full bottles. Also means the product never went through a traditional full fermentation cycle in its final form.

Is it still kombucha?

The industry argues about this constantly. More on that in a minute.

Here's what the scale game looks like at ground level in New Zealand.

Batchwell. Auckland-based. Metro ranked them the best kombucha in the country. Got squeezed out of Countdown (now Woolworths NZ). Couldn't generate enough velocity against $2.99 Remedy sitting right next to them. When your product is $5.39 and the competitor runs specials under $3, the shopper doesn't care about traditional brewing.

Banjo Brews. Another NZ craft operation. Shut down entirely after seven years. Once the big Australian brands entered the market, the economics stopped working.

Total annual NZ supermarket kombucha sales hit $30.7 million in FY21. Most of that revenue flows to Melbourne.

Batchwell's response has been to raise capital ($700K to $1M via Snowball Effect), launch an alcoholic kombucha line (Blume), and try to diversify out of a category where the structural economics crush small players. Revenue was at $630,000. They forecast $4.26 million by FY23. Whether they reached it is another question entirely.

But the strategy tells you the story.

You can't win on kombucha alone in a market where the Australians set the floor price.

The Erythritol Question

Here's where it gets properly interesting.

Flip over a bottle of Remedy. Read the full ingredients list.

Certified Organic Raw Kombucha (Sparkling Water, Wild Kombucha Culture, Black Tea, Green Tea), Plant-based Sweeteners (Erythritol, Steviol Glycosides), Ginger Juice, Lemon Juice, Natural Ginger Flavour.

Erythritol and stevia. That's how Remedy gets to "no sugar." They ferment the tea, the SCOBY eats the sugar, then they add non-fermentable sweeteners back in so it doesn't taste like vinegar. Technically sugar-free because erythritol and stevia don't register on a nutrition panel.

Lo Bros runs the same play. Erythritol. Stevia. Juice concentrate. Probiotics added after production.

Now read the label on a Good Buzz from Tauranga. No erythritol. No stevia. Traditionally brewed, raw, unpasteurised. The sugar content is higher because there's no artificial sweetening, but the fermentation is real and uninterrupted.

This is the core tension in the entire category.

The cheap, dominant brands use a production method that purists consider borderline fraudulent. The authentic craft brands can't compete on price because genuine full-cycle fermentation is slower, requires cold chain from day one, and produces a less shelf-stable product.

Right now, there's no regulation that says a kombucha has to be traditionally fermented. You can brew concentrate, dilute it, add sweeteners and probiotics, call it kombucha, and retail it for $2.99.

The consumer thinks they're buying a probiotic health drink. What they're often getting is flavoured sparkling water with erythritol and a fermentation backstory.

That $1 million GT Dave donated to KBI? It was an attempt to draw a line. To create a standard of identity that would separate real kombucha from kombucha-flavoured soft drink. The fact that a billionaire had to fund it personally tells you where the regulatory priority sits.

Somewhere below "we'll get to it eventually."

The Shelf Is Getting Blurry

Walk two feet to the right in that same supermarket fridge.

Remedy Switchel ACV. Same branding. Same shelf. Made from apple cider vinegar and ginger instead of tea and a SCOBY.

Kombucha. ACV drinks. Prebiotic sodas. Probiotic shots. Kefir. All fighting for the same fridge real estate, the same health-conscious consumer, the same "gut health" positioning. The category descriptor on every NZ supermarket website now reads "Kombucha & Functional Drinks." The line between these products has evaporated.

Remedy saw this years ago. Their range now spans Remedy Kombucha, Remedy Sodaly (a prebiotic soft drink), Remedy KICK (a natural energy drink), Remedy Shots, and Remedy Switchel ACV. This isn't a kombucha company anymore. It's a functional beverage platform using fermentation as a brand story.

The economics are almost identical across every product in the fridge. Base ingredients cost cents. Fermentation (if it happens at all) costs time and space. The bottle, the label, the cold chain, and the marketing cost real money.

For NZ craft producers like Tempus Tonics in Matakana or Ceres Organics, the challenge mirrors what's happening in kombucha: Remedy slaps a new label on essentially the same production process and fills every Woolworths fridge in the country at a price nobody small can touch.

Where The White Space Actually Is

So if you're an operator looking at this category, where's the opportunity?

It's not in launching another kombucha brand. The category is locked between Australian scale players at the bottom and struggling craft brewers at the top. The middle is a graveyard.

But there are gaps. Real ones.

Hard kombucha. Batchwell went here with Blume. Alcoholic kombucha straddles the RTD category and the health-conscious drinking trend. Different buyer, different occasion, different margin structure. The RTD market is enormous compared to the kombucha category. And in New Zealand, the overlap between "people who drink RTDs" and "people who care about gut health" is growing fast.

Direct-to-consumer subscription. Skip the supermarket entirely. Good Buzz's taproom model in Tauranga is one approach. Monthly subscription boxes another. That 30-40% margin you surrender to Woolworths on every bottle? Goes straight back to the brewer. The customer relationship becomes yours, not theirs.

Functional ingredients without fermentation. This is where the real money is moving. Ditch the SCOBY. Add prebiotics, adaptogens, or functional fibres to carbonated water. Shelf-stable. No cold chain. Lower COGS. Bigger addressable market because you're competing with Coke, not other kombucha brands. Olipop has done exactly this in the US and hit $500 million in annual retail sales. No fermentation required. Same gut health narrative. Dramatically better unit economics.

The kefir gap. Coconut water kefir (Dannic Drinks is already doing this in NZ) has almost zero mainstream retail penetration. The gut health story is arguably stronger than kombucha, the production is simpler, and the competitive set barely exists. If you're looking for a category with white space and a genuine product story, this is it.

The functional beverage aisle is wide open if you stop trying to make kombucha and start thinking about what the consumer actually wants. Something fizzy that makes them feel healthy. The SCOBY is optional.

The Structural Lock

The kombucha market follows the same arc as craft beer a decade ago. Pioneers build the category. Consumers develop a taste. Scale players enter, compress pricing, and the pioneers consolidate, exit, or retreat to niches.

Cold chain costs are brutal in New Zealand. Genuine kombucha (unpasteurised, live cultures) needs refrigeration from brewery to shelf. In a country of 5 million spread across two islands, that cost per unit is punishing. Remedy absorbs it through volume. A small Tauranga brewer shipping to Wellington cannot.

The duopoly controls access. Woolworths NZ and Foodstuffs together hold roughly 90% of grocery retail. Getting listed requires volume commitments, promotional budgets, and pricing that competes with shelf leaders. For a craft brewer producing a genuinely superior product at $5+ per bottle, the numbers don't close.

The health halo is unregulated. Remedy and Lo Bros market gut health, probiotics, and "no sugar" just as aggressively as the authentic brewers. No labelling differentiates "traditionally fermented over 30 days" from "made from concentrate with probiotics added after." Consumer defaults to price. Price favours scale. Always has.

This dynamic isn't unique to New Zealand. It's playing out globally. Health-Ade sold for $500 million. PepsiCo bought KeVita for $200 million. GT Dave's company is worth over $900 million. The exits are real. So is the graveyard of small brewers who never reached the scale required to survive.

What Operators Should Take From This

The ingredient cost is almost irrelevant. Tea, sugar, water, a culture. Cents per bottle. The cost that matters is everything after the SCOBY does its job: packaging, cold chain, marketing, shelf access. That's 70% to 80% of the retail price.

The global market is somewhere between $3 billion and $5 billion, heading toward $10 billion by end of decade. But category growth doesn't guarantee everyone wins. It usually means the scale players take a larger share of a bigger pie.

If your business plan depends on the consumer paying $6 for something that looks identical to the $3 option sitting right next to it, you need a distribution strategy that puts you somewhere the $3 option isn't. Or you need to stop making kombucha and start building what comes after it.

The next generation of functional beverage brands has already figured out you don't need a SCOBY to sell gut health. You just need fibre, fizz, and a story the consumer wants to believe.

The fermentation is optional. The margin isn't.

Shoutout to the legends whose work informed this piece:

Newsroom | Metro | The Hustle | Inc. Magazine | CNBC Make It | Wikipedia | Food Dive | BusinessWire | BevNET | Fortune | NZ Herald | NZBusiness | Grand View Research | Mordor Intelligence | Market Data Forecast | Startup Financial Projection | Financial Models Lab | Remedy Drinks NZ | Good Buzz | Batchwell | Food & Beverage Industry News | Booch News